Vivo Cannabis Inc (fka VVCIF)

[NetworkNewsWire]

Cannabis Demand in Canada Creates Considerable Opportunity for ABCCF

As Canada prepares for the legalization of recreational marijuana in July 2018, analysts are noting a shortage of supplies compared to expected demand for cannabis products. The demand is expected to exceed about 1.3 million pounds, easily outpacing current annual production of 20,000 pounds by the country’s licensed producers. That creates tremendous opportunities for Canada’s top cultivators with the ability to expand their operations and increase supply. An article discussing this reads: “ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), has been licensed in good standing since 2014 with no history of product recalls, and proprietary computer-controlled production systems that have bolstered the company’s reputation for its consistent pharmaceutical-grade cannabis. Recognizing early on that if the plant was to be effectively utilized as medicine, production had to be standardized from batch to batch, year-over-year, ABcann took an unprecedented scientific approach to medical cannabis production and established a $1.5 million research contract with the University of Guelph, a world leader in controlled environmental growth systems. The scientific collaboration led to ABcann’s proprietary cultivation methods that produce the highest consistent quality cannabis with yields that double the industry standards.”

To read the full article, visit http://nnw.fm/fe8K0

About ABcann Global Corp.

ABcann holds production and sales licenses from Health Canada. Its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centered on its specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade cannabis products. The company is expanding its cultivation capacity and pursuing partnership and product development opportunities domestically, as well as in select international markets, such as Germany, Australia and Israel. For more information, visit www.ABcannGlobal.com.